Paper Review Records
All Paper Review Records
10 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
54
days
High rates of venous thromboembolism in endometrial cancer patients requiring systemic therapy: an opportunity for risk assessment and intervention
AuthorsElizabeth G. Thayer; Zoe A. Roecker; Kelsey A. Roof; Hannah B. Gold; Kristen D. Starbuck
AffiliationsDepartment of Gynecology and Obstetrics, Emory University School of Medicine, USA; Emory University School of Medicine, USA; Division of Gynecologic Oncology, Department of Gynecology and Obstetrics, Emory University School of Medicine, USA
139
days
Leveraging artificial intelligence in the early detection of ovarian cancer: Development and validation of a risk prediction model
AuthorsGraham C. Chapman; Oleksii Fedorenko; David Sheyn; Allison Reid; Lauren Taylor; Soumya Ray; Sarah K. Lynam
AffiliationsDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, University Hospitals Cleveland Medical Center, 11100 Euclid Ave, Cleveland, OH 44106, United States of America; Case Western Reserve University School of Medicine, 2109 Adelbert Rd., Cleveland, OH 44106, United States of America; Urology Institute, University Hospitals Cleveland Medical Center, 11100 Euclid Ave, Cleveland, OH 44106, United States of America
65
days
Early-phase vs. late-phase clinical trials in gynecologic oncology: Trends in trial completion, reporting, and enrollment of racial and ethnic minority groups
AuthorsMichael T. Richardson; Danika Barry; Jecca R. Steinberg; Kai Holder; Vineeth Thirunavu; Naixin Zhang; Brandon E. Turner; Christopher J. Magnani; Anna Marie P. Young; Connie F. Lu; Natalie A. Squires; Jill N. Anderson; Joshua Cohen; Beth Y. Karlan; John K. Chan; Daniel S. Kapp; Dario R. Roque; Ritu Salani
AffiliationsDepartment of Obstetrics and Gynecology, University of California Los Angeles, Los Angeles, CA, United States; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Brigham and Women's Hospital, Boston, MA, United States; Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California San Francisco, San Francisco, CA, United States; Department of Obstetrics, Gynecology, and Reproductive Sciences, University of Pittsburgh, Pittsburgh, PA, United States; Department of Obstetrics and Gynecology, Northwestern University Feinberg School of Medicine, Chicago, IL, United States; Division of Gynecologic Oncology, University of Rochester Medical Center, Rochester, NY, United States; Harvard Radiation Oncology Program, Boston, MA, United States; Department of Urology, Brigham & Women's Hospital and Harvard Medical School, Boston, MA, United States; Department of Maternal Fetal Medicine, Brown University/Women and Infants of Rhode Island, Providence, RI, United States; Department of Obstetrics & Gynecology, University of Illinois Chicago, Chicago, IL, United States; Department of Obstetrics and Gynecology, New York-Presbyterian/Weill Cornell Medical Center, New York, NY, United States; Division of Gynecologic Oncology, Department of Surgery, City of Hope Orange County Lennar Foundation Cancer Center, Irvine, CA, USA; California Pacific / Palo Alto Medical Foundation / Sutter Research Institute, San Francisco, CA, United States; Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, United States
146
days
Comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in patients with newly diagnosed homologous recombination–deficient stage III/IV ovarian cancer: Findings from cohort C of the OPAL phase 2 trial
AuthorsShannon N. Westin; Jimmy Belotte; Brunella Felicetti; Vishvajit Aghera; Ahmed YoussefAgha; Evi Bakirtzi; Ana Godoy Ortiz; Arantzazu Barquín García; Diane Provencher; Raúl Márquez Vázquez; Lucia González Cortijo; Xing Zeng; Dan-Arin Silasi; Leslie S. Bradford; Fernanda B. Musa; John K. Chan; Joyce F. Liu; Luis Rojas-Espaillat
AffiliationsDepartment of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; GSK, Waltham, MA, USA; GSK, Stevenage, UK; GSK, Mississauga, Ontario, Canada; GSK, London, UK; Medical Oncology Unit, Virgen de la Victoria University Hospital and Málaga Regional University Hospital, Málaga, Spain; IBIMA Plataforma BIONAND, Málaga, Spain; Genitourinary, Gynecological & Skin Cancer Unit Centro Integral Oncologico HM Clara Campal, Madrid, Spain; Centre Hospitalier de l'Université de Montréal, Université de Montréal and Institut du Cancer de Montréal, Montreal, Quebec, Canada; MD Anderson Madrid, Madrid, Spain; Medical Oncology, Quirónsalud, Madrid, Spain; McGill University Health Centre, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Montreal, Quebec, Canada; Division of Gynecologic Oncology, McGovern Medical School, UTHealth, Houston, TX, USA; MaineHealth Gynecology Cancer Care, Scarborough, ME, USA; Providence-Swedish Cancer Institute, Seattle, WA, USA; Division of Gynecologic Oncology, California Pacific Medical Center, Palo Alto Medical Foundation, Sutter Cancer Research Consortium, San Francisco, CA, USA; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA; Avera Medical Group Gynecologic Oncology, Sioux Falls, SD, USA
31
days
Incidence, prevalence, mortality and survival trends in women with endometrial-, ovarian- and cervical cancer in the Nordic countries (1980–2023) with focus on younger women (0–49 years old)
AuthorsCharlotta Riese; Enoch Yi-Tung Chen; Hanna Nilsson; Sahar Salehi; Anna Sara Oberg; Simon Mathis Kønig; Richard G. Feltbower; Christine Rousset-Jablonski; Magdalena Balcerek; Kenny Rodriguez-Wallberg
AffiliationsDepartment of Oncology-Pathology, Karolinska Institute, Karolinska Institutet, Stockholm, Sweden; Division of Clinical Epidemiology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden; Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; Cancer Epidemiology and Surveillance, Danish Cancer Institute, Danish Cancer Society, Copenhagen, Denmark; Child Health Outcomes Research at Leeds (CHORAL), University of Leeds, Leeds, UK; Léon Bérard Cancer Center, Femme Mère Enfant Hospital, Hospices civils de Lyon, and INSERM U1290 RESHAPE, Lyon, France; Department of Oncology, Hepatology and Pneumology, University Hospital Leipzig and University Cancer Center Leipzig, Leipzig, Germany; Department of Reproductive Medicine, Division of Gynecology and Reproduction, Karolinska University Hospital, Stockholm, Sweden
48
days
Predicting residual disease and extent of surgery after neoadjuvant chemotherapy for ovarian cancer: Does the MSKCC model from the primary setting apply?
AuthorsChiara Ainio; Giuseppe Caruso; Sarah Alessi; Annapaola Antonia Aiello; Giuseppe Petralia; Marina N. Rosanu; Lucia Ribero; Pamela I. Causa-Andrieu; Ceylan Colak; Alan H. Stolpen; Luigi A. De Vitis; Amanika Kumar; Carrie L. Langstraat; Michaela E. McGree; Francesco Multinu; Stuart A. Ostby; Gabriella Schivardi; Amanda L. Tapia; Nicoletta Colombo; Giovanni D. Aletti; William A. Cliby
AffiliationsDepartment of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN, USA; Division of Radiology, European Institute of Oncology (IEO), Milan, Italy; Division of Gynecologic Oncology, European Institute of Milan (IEO), IRCCS Milan, Italy; Department of Radiology, Mayo Clinic, Rochester, MN, USA; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA; Department of Oncology and Hematology-Oncology, University of Milan, Milan, Italy
35
days
Persistent low-level real human chorionic gonadotropin after gestational trophoblastic disease: Natural history and predictors of subsequent gestational trophoblastic neoplasia
AuthorsRaphael Alevato; Antônio Braga; Gabriela Paiva; Edward Araujo Júnior; Sue Yazaki Sun; Luana Giongo Pedrotti; Marina Bessel; Solange Artimos de Oliveira; Joffre Amim-Junior; Jorge Rezende-Filho; Ross Berkowitz; Neil Horowitz
AffiliationsSchool of Medicine, Fluminense Federal University, Niterói, RJ 24070-090, Brazil; Department of Gynecology and Obstetrics, School of Medicine, Maternity School, Federal University of Rio de Janeiro, Rio de Janeiro, RJ 22240-003, Brazil; Department of General and Specialized Surgery, School of Medicine and Surgery, Federal University of the State of Rio de Janeiro, Rio de Janeiro, RJ 20270-004, Brazil; University of Vassouras, Vassouras, RJ 27700-000, Brazil; Department of Obstetrics, Paulista School of Medicine, Federal University of São Paulo (EPM-UNIFESP), São Paulo 04023-062, SP, Brazil; Hospital Moinhos de Vento, Porto Alegre, RS, Brazil; New England Trophoblastic Disease Center, Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Biology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA
37
days
Dynamics of HER2 status in recurrent cervical cancer: Highlighting the clinical value of reassessment
AuthorsJun-Hyeong Seo; Yurimi Lee; Seongyun Lim; Young Eun Chung; Yoo-Young Lee; Chel-Hun Choi; Hyun-Soo Kim; Jeong-Won Lee
AffiliationsDepartment of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
72
days
A phase II study of androgen receptor inhibition by darolutamide in combination with leuprolide acetate and exemestane in recurrent adult-type ovarian granulosa cell tumor
AuthorsElizabeth E. Hopp; Danielle Enserro; Susana Campos; Viola Chitiyo; Gloria Huang; Heather Lankes; Erin K. Crane; Anna Hoekstra; Jean Siedel; Debra L. Richardson; Carol Aghajanian; Janet S. Rader; Allan Covens
AffiliationsMedical College of Wisconsin Cancer Center, Department of Obstetrics and Gynecology, 8701 W Watertown Plank Rd Milwaukee, WI 53226, USA; NRG Oncology, CTDD Biostatistics & Bioinformatics; Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA; Dana Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, USA; Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA; Yale Cancer Center, 35 Park St, New Haven, CT 06519, USA; Division of Gynecologic Oncology, Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA; Levine Cancer Atrium Health Wake Forest Baptist, 1021 Morehead Medical Drive Charlotte, NC 28204, USA; CRC West Michigan Cancer Center, 200 North Park St, Kalamazoo, MI 49007, USA; University of Michigan, 1500 E Medical Center Dr, Ann Arbor, MI 48109, USA; University of Oklahoma, 800 NE 10th Street, Oklahoma City, OK 73104, USA; University of Toronto, Sunnybrook Health Centre, Odette Cancer Centre, 2075 Bayview Ave, Toronto, ON, M4N 3M5, Canada
72
days
Quality of life outcomes after sentinel lymph node biopsy in patients with early-stage cervical cancer: Results from the prospective multicentre SENTIX study
AuthorsRoman Kocian; Christhardt Koehler; Giampaolo Di Martino; Jaroslav Klat; Luc van Lonkhuijzen; Jiri Jarkovsky; Michal Zikan; Ignacio Zapardiel; Octavio Arencibia Sanchez; Blanca Gil-Ibanez; Francesco Raspagliesi; Jiri Presl; Lubos Minar; Radim Marek; Peter Kascak; Pavel Havelka; Martin Michal; Toon Van Gorp; Kristyna Nemejcova; Pavel Dundr; Sambor Sawicki; Martina Borcinová; David Cibula
AffiliationsGynecologic Oncology Center, Department of Gynecology, Obstetrics and Neonatology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic; Department of Obstetrics and Gynecology, Albertinen Hospital Hamburg, Germany; Department of Obstetrics and Gynecology, University Hospital Ostrava, Ostrava, Poruba, Czech Republic; Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic; Gynecologic Oncology Unit, La Paz University Hospital, Madrid, Spain; Department of Gynecologic Oncology, Amsterdam University Medical Center, Center for Gynecological Oncology Amsterdam, Amsterdam, Netherlands; Department of Obstetrics and Gynecology, Bulovka University Hospital, First Faculty of Medicine, Charles University, Prague, Czech Republic; Department of Gynecologic Oncology, University Hospital of the Canary Islands, Las Palmas de Gran Canaria, Spain; Unit of Gynecological Oncology, Institute Clinic of Gynecology, Obstetrics and Neonatology (ICGON), Hospital Clinic of Barcelona, Barcelona, Spain; Department of Gynecological Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Italy; Department of Gynecology and Obstetrics, University Hospital Pilsen, Charles University, Faculty of Medicine in Pilsen, Pilsen, Czech Republic; Department of Gynecology and Obstetrics, Faculty of Medicine, Masaryk University, University Hospital Brno, Brno, Czech Republic; Department of Obstetrics and Gynecology, Faculty of Medicine and Dentistry, Palacky University, University Hospital Olomouc, Olomouc, Czech Republic; Department of Gynecology and Obstetrics, Slovak Medical University and University Hospital, Bratislava, Slovak Republic; Department of Obstetrics and Gynecology, KNTB a.s, Zlin, Czech Republic; Department of Obstetrics and Gynecology, Hospital Ceske Budejovice, JSC, Ceske Budejovice, Czech Republic; Department of Gynaecological Oncology, University Hospital Leuven, Leuven Cancer Institute, Leuven, Belgium; Department of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic; Gynecologic Oncology Surgical Division, Humanitas San Pio X, Milan 20159, Italy; Gynecology Unit, IRCCS Fondazione San Gerardo dei Tintori, 20900 Monza, Italy; Department of Obstetrics, Gynaecology and Neonatology, Medical University of Gdansk, Poland
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
Client
I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?
CrushSCI
Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.
- Suggested title
- Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment
- Database shortlist
- Environmental Technology & Innovation
SampleLatest 5 valid paper samples from 2026
Average review96.4 days
Median77 days